Nasdaq:EWTX
Edgewise Therapeutics, Inc.
A clinical-stage biotech firm leveraging a proprietary platform to develop next-generation therapies for rare diseases with significant unmet medical needs.
Key Metrics
Investment Thesis
Bull Case
Investors may consider Edgewise for its high-risk, high-reward potential in the lucrative orphan drug market where successful candidates can command substantial pricing power and exclusivity. The company's ability to secure nearly $200M in financing recently suggests strong investor confidence in its scientific platform and milestone achievements. If any clinical trials succeed, the value of the pipeline could appreciate significantly as the company transitions from a cash-burn entity to one generating commercial revenue.
Bear Case
The stock carries extreme risk given the complete lack of revenue and a deepening annual net loss that has nearly doubled over the last three years. Investors must be concerned about ongoing dilution, as recent financing rounds have involved nearly $187M in new shares to fund operations costing over $190M annually. The probability of clinical failure remains high for early-stage assets, and the company may never achieve a positive cash flow without additional successful partnerships or sales.
About Edgewise Therapeutics, Inc.
Edgewise Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for rare diseases, primarily targeting the orphan drug market in the United States. The company leverages its proprietary technology platform to advance high-value candidates through preclinical and clinical development stages with the goal of commercialization upon regulatory approval.
Analysis
Management Discussion
Edgewise Therapeutics reported a net loss of $167.8M for the most recent period, continuing a trend of widening losses from -$67.6M in 2022 to -$133.8M in 2024 as it scales its R&D efforts with $151.4M spent on research and development. Despite heavy operating expenses totaling $191.4M, the company maintained a robust cash position with $61.1M in cash and equivalents after a net change in cash of $19.5M, supported by significant financing inflows. The balance sheet shows strong equity at $522.3M against low current liabilities of $27.4M, indicating adequate liquidity management despite the lack of commercial revenue.
Industry Overview
The biotechnology sector is characterized by intense competition and long development timelines, particularly within the rare disease space where regulatory pathways like Orphan Drug Designation offer exclusivity but require substantial investment. Companies in this niche often rely on strategic alliances with large pharmaceutical firms to share development costs and de-risk their pipelines before commercial launch. Market dynamics favor firms that can demonstrate scientific innovation and secure favorable regulatory outcomes for their most advanced assets.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| Operating Expenses | $71.7M | $114.4M | $158.8M | $191.4M |
| Operating Income | $-71.7M | $-114.4M | $-158.8M | $-191.4M |
| R&D | $54.0M | $90.9M | $127.0M | $151.4M |
| G&A | $17.6M | $23.5M | $31.9M | $40.0M |
| Stock-Based Comp | $10.9M | $17.6M | $24.7M | $34.8M |
| Depreciation | $368.0K | $1.6M | $2.1M | $2.1M |
| Other OpEx | $0 | $0 | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 | $23.6M |
| Interest Income | $4.0M | $14.2M | $25.0M | $23.6M |
| Pre-Tax Income | $-71.7M | $-114.4M | $-158.8M | $-167.8M |
| Income Tax | $0 | $0 | $0 | $4.0K |
| Continuing Ops | $-71.7M | $-114.4M | $-158.8M | $-167.8M |
| Discontinued Ops | $0 | $0 | $0 | $9.0K |
| Net Income | $-67.6M | $-100.2M | $-133.8M | $-167.8M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-67.6M | $-100.2M | $-133.8M | $-167.8M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $357.0M | $327.0M | $475.5M | $543.4M |
| Cash & Equivalents | $22.0M | $86.1M | $41.7M | $61.1M |
| Prepaid Expenses | $5.1M | $8.6M | $5.3M | $13.3M |
| Other Current Assets | $330.0M | $232.3M | $428.5M | $469.0M |
| Long-Term Assets | $10.1M | $13.0M | $11.3M | $9.2M |
| PP&E (Net) | $8.5M | $10.4M | $9.5M | $7.8M |
| Operating Leases | $1.3M | $2.2M | $1.6M | $1.4M |
| Other LT Assets | $251.0K | $348.0K | $262.0K | $0 |
| Total Assets | $367.1M | $340.0M | $486.8M | $552.6M |
| Current Liabilities | $16.6M | $16.8M | $23.9M | $27.4M |
| Accounts Payable | $6.1M | $4.0M | $5.6M | $6.0M |
| Current Leases | $608.0K | $980.0K | $996.0K | $1.0M |
| Other Current Liab | $4.0M | $5.7M | $10.1M | $12.4M |
| Long-Term Liabilities | $3.8M | $4.4M | $3.7M | $3.0M |
| LT Operating Leases | $3.8M | $4.4M | $3.7M | $3.0M |
| Other LT Liab | $0 | $0 | $0 | $0 |
| Total Liabilities | $20.4M | $21.2M | $27.6M | $30.3M |
| Shareholders' Equity | $346.7M | $318.8M | $459.2M | $522.3M |
| Paid-In Capital | $492.7M | $563.5M | $837.4M | $1.07B |
| Retained Earnings | $-144.6M | $-244.8M | $-378.6M | $-546.4M |
| AOCI | $-1.4M | $99.0K | $420.0K | $677.0K |
| Total L&E | $367.1M | $340.0M | $486.8M | $552.6M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-67.6M | $-100.2M | $-133.8M | $-167.8M |
| Non-Cash Adjustments | $8.0M | $2.7M | $21.0M | $13.4M |
| Working Capital Changes | $7.0M | $5.5M | $3.7M | $10.6M |
| Cash from Operations | $-52.6M | $-91.9M | $-109.0M | $-143.8M |
| Capital Expenditures | $5.5M | $5.7M | $1.3M | $256.0K |
| Cash from Investing | $-70.6M | $102.9M | $-184.7M | $-32.8M |
| Cash from Financing | $129.6M | $53.2M | $249.3M | $196.1M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $6.4M | $64.1M | $-44.4M | $19.5M |
| Beginning Cash | $15.6M | $22.0M | $86.1M | $41.7M |
| Ending Cash | $22.0M | $86.1M | $41.7M | $61.1M |
Frequently Asked Questions
How does Edgewise Therapeutics, Inc. make money?
The company operates primarily through its core therapeutic development pipeline, focusing on advancing multiple candidates from preclinical research through Phase 1 and beyond. Revenue generation is currently driven by grants, strategic collaborations, and potential milestone payments rather than commercial product sales, reflecting its status as a clinical-stage entity with zero reported revenue.
What are the main risks for EWTX?
The company carries substantial dilution risk due to its reliance on equity financing, evidenced by recent cash flow from financing of $196.1M and common share issuances of $187.4M over the reporting period. As a pre-revenue biotech firm with a significant accumulated deficit of -$546.4M, Edgewise faces high burn rates and an uncertain path to profitability dependent on successful clinical trials. Regulatory hurdles in orphan drug development could delay or prevent market entry for its pipeline candidates. The company's liquidity depends heavily on external capital markets; adverse conditions could restrict access to necessary funding for ongoing operations.
What is EWTX's competitive advantage?
The company possesses a differentiated proprietary technology platform capable of generating novel drug candidates for rare diseases that are difficult to address with traditional methods. Its strategic focus on orphan indications allows it to leverage significant government incentives and market exclusivity periods upon approval. The management team has demonstrated the ability to advance multiple assets simultaneously while maintaining a lean operational cost structure relative to its asset size.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.